Financial Data and Key Metrics Changes - Full-year revenue for 2025 was $121.6 million, representing a 5% increase from 2024 [7][16] - Q4 revenue was $29.5 million, a 3% decrease from Q3 and a 34% decline year-over-year [16] - Full-year swap volume reached $6.89 billion, a 21% increase from 2024, while Q4 swap volume was $1.59 billion, down 9% sequentially and down 32% year-over-year [16][17] - Revenue from staking nearly doubled to over $4 million, driven by improvements in Solana staking [17] Business Line Data and Key Metrics Changes - XO Swap, the B2B swaps platform, generated $416 million in Q4 volume, accounting for 26% of total quarterly volume [17] - Fiat onboarding revenue increased by 28% compared to 2024 [17] - Funded users at the end of the year were 1.7 million, down 6% from the previous quarter and 11% year-over-year [17] Market Data and Key Metrics Changes - The broader retail environment impacted the number of monthly active users, which declined to 1.5 million, down 35% year-over-year [18] - The decline in digital asset prices during Q4 affected overall revenue and trading activity [16][18] Company Strategy and Development Direction - The company is transitioning from a speculation-driven model to a payments-focused model, aiming to create revenue streams independent of cryptocurrency market fluctuations [7][14] - Exodus Pay is central to this strategy, designed to integrate various financial services into a single app, making it user-friendly and accessible [9][45] - The W3C acquisition is a key part of the vertical integration strategy, allowing the company to own the full payment stack and diversify revenue [10][11] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges faced in 2025 but emphasized the importance of building infrastructure to reduce dependency on market conditions [5][14] - The company is optimistic about the future, with expectations that investments made in 2025 will start to yield results in 2026 [14] - AI is seen as a transformative factor, with potential to create a new class of customers needing wallet infrastructure [12] Other Important Information - The company is pausing Bitcoin dividend plans to prioritize M&A and growth initiatives [19] - The integration of AI tools is enhancing productivity within the engineering team [12] Q&A Session Summary Question: Can you expand on the steps needed for agentic payments? - Management discussed the need for secure wallet infrastructure to enable AI agents to transact, emphasizing user control over wallets and the importance of security measures [23][28] Question: What about the cost structure and one-time expenses in Q4? - Management noted legal costs and interest related to the Galaxy loan as part of the cost structure, with expectations for slightly lower costs moving forward [30][31] Question: What are the drivers behind improved monetization in XO Swap? - Management highlighted the growth in the number of partners and the expectation of continued growth in the B2B2C model, despite potential fluctuations in partner operations [35][36] Question: When will the next wave of XO Swap partners ramp up? - Management indicated steady growth and the anticipation of announcing significant new partners in the future, while emphasizing the integration timeline for partners [39][41] Question: How will capital be allocated for consumer-facing initiatives? - Management reiterated that Exodus Pay is an evolution of the company, focusing on consumer needs and aligning capital allocation with mainstream market demands [61][68]

Summary of SLM (Sallie Mae) Conference Call Company Overview - **Company Name**: Sallie Mae (SLM) - **Industry**: Private Student Lending - **Company Age**: Over 50 years, with the current version established about 12-15 years ago - **Core Business**: Focused on providing private student loans after students have exhausted free financial aid options [12][13] Key Financial Metrics - **Average Loan Amount**: Approximately $12,000-$13,000 per loan - **Average Number of Loans per Customer**: 1.5 loans - **Loan Repayment Period**: About 7 years - **Annual Net Charge-off Rate**: Approximately 2%, indicating low default risk [14][15] Customer Acquisition and Success - **Customer Acquisition**: Engages with about 4 million customers annually, representing roughly two-thirds of high school seniors transitioning to college [21] - **Focus on Student Success**: Aims to be a comprehensive education solutions provider, assisting with scholarships and federal loan applications [22] Recent Achievements - **Share Buyback**: Approximately 55% of shares outstanding repurchased over the last five and a half years, contributing to total shareholder returns [25] - **Securitization**: Completed the first on-book securitization of the year at favorable pricing, indicating strength in underlying assets [29][38] - **Loan Sale**: Reached indicative terms on a $2 billion loan sale expected to close in Q1, enhancing capital return strategies [31] Market Dynamics and AI Impact - **AI Concerns**: Acknowledges the potential impact of AI on job markets but believes it will lead to nuanced changes rather than outright job losses [50][51] - **College Graduate Resilience**: Recent college graduate unemployment rates have shown resilience, with the gap closing from 1.3-1.4 percentage points higher last summer to just 0.1% currently [54] Grad PLUS Program and Future Opportunities - **Grad PLUS Reforms**: Anticipates $4.5-$5 billion in annual originations from the Grad PLUS program, which caps federal involvement and aims to reduce student debt levels [69][70] - **Investment in Infrastructure**: Plans to invest in resources and capabilities to handle increased volume from the new Grad PLUS program [72][74] Competitive Landscape - **Market Competition**: Expects a competitive environment as the federal government steps back, creating opportunities for private lenders [79] - **Strategic Partnerships**: Engaged in a partnership with KKR to optimize funding sources and enhance capital return strategies [87] Credit Outlook - **Stable Credit Expectations**: Guidance indicates a stable credit outlook for the upcoming year, with ongoing monitoring of loan modification programs [91][93] Conclusion - **Overall Sentiment**: The company expresses optimism about future growth opportunities, particularly with the implementation of Grad PLUS reforms and the resilience of its customer base [57][78]

ImmunityBio Conference Call Summary Company Overview - **Company**: ImmunityBio (NasdaqGS: IBRX) - **Industry**: Immunotherapy, specifically focusing on cancer treatment Key Points and Arguments 1. **Leadership and Vision**: ImmunityBio is led by Dr. Patrick Soon-Shiong, who has a long-term vision for the company, focusing on combination therapies to combat cancer. The company has been executing this vision since 2010, with significant developments expected in the coming years [2][3] 2. **Product Approval and Market Expansion**: - The company's product, ANKTIVA, is approved in 33 countries for non-muscle invasive bladder cancer, specifically in the BCG unresponsive space. A submission for approval in the papillary disease area has been made to the U.S. FDA [4][7] - ANKTIVA has shown significant revenue growth, attributed to a dedicated commercial team [7][10] 3. **Clinical Trials and Data**: - The naïve study for ANKTIVA has been fully enrolled, with results expected in mid-2026. The company plans to submit a supplemental Biologics License Application (sBLA) by the end of 2026 [9][10] - ANKTIVA has demonstrated a median duration of response of 53 months, significantly outperforming competitors [13][14] 4. **Market Opportunities**: - The total addressable market (TAM) for bladder cancer is estimated to be multi-billion dollars, with J&J estimating it at $5 billion. The company sees endless market opportunities across various cancer types, including lung cancer and lymphopenia [47][48] - Saudi Arabia has approved ANKTIVA for non-small cell lung cancer, marking a significant milestone for the company [10][11] 5. **Innovative Therapies**: - ImmunityBio is developing a world bank of natural killer (NK) cells and CAR NK therapies, which are expected to enhance treatment options for various cancers [6][10] - The company is also working on a recombinant BCG product in collaboration with the Serum Institute of India, aimed at addressing the BCG shortage [22][23] 6. **Patient-Centric Approach**: - The company emphasizes the importance of patient stories and outcomes, showcasing the transformative impact of their therapies on patients' lives [41][42] - ANKTIVA is recognized as a lymphocyte-stimulating agent, which is crucial for improving patient outcomes in cancer care [42][43] Other Important Content - **Sales Growth**: ImmunityBio reported a 700% year-over-year sales growth, with unit sales increasing by 750%, indicating strong market demand for ANKTIVA [17] - **Regulatory Engagement**: The company is actively engaging with regulatory bodies, with expectations for FDA acceptance of their recent filing and ongoing discussions with the National Comprehensive Cancer Network (NCCN) [49][50] - **Global Expansion**: ImmunityBio aims to become a global company by 2026, with substantial revenue expected in 2027 [51] This summary encapsulates the critical insights from the ImmunityBio conference call, highlighting the company's strategic direction, product developments, and market potential in the immunotherapy landscape.

Financial Data and Key Metrics Changes - For Q4 2025, the company reported revenue of $397.6 million, a 17% year-over-year increase, with organic growth of 12% [19] - Adjusted EBITDA grew 53% year-over-year to $39.5 million, with margins expanding to 9.9% [22] - Full-year 2025 adjusted EBITDA was $115 million, exceeding previous guidance [25] - The company increased its cash balance to $66 million, up from $36 million in Q3 2025 [22] Business Line Data and Key Metrics Changes - The company served over 205,000 residents, a 10% increase year-over-year [19] - Script volume grew 14% year-over-year, with vaccine script volumes up 3% [19][20] - Gross profit rose 27% to $85.5 million, with gross margins expanding to 21.5% from 19.8% [19] Market Data and Key Metrics Changes - The company anticipates a revenue forecast of $1.4 billion to $1.42 billion for 2026, reflecting new pricing impacts from the IRA [26] - The long-term care pharmacy environment is evolving with ongoing consolidation and increasing operational complexity [13] Company Strategy and Development Direction - The company plans to continue investing in acquisitions and greenfield startups while enhancing data analytics capabilities [8] - The company aims to offset anticipated EBITDA impacts from the IRA and maintain service levels during industry transitions [12][11] - The focus remains on supporting partners with reliable execution amid industry changes [14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth momentum despite industry challenges, raising 2026 adjusted EBITDA guidance to $120 million-$124 million [17][26] - The demographic shift with the aging population is expected to create incremental tailwinds for the company [13] - Management is closely monitoring the operational complexities introduced by the IRA [11] Other Important Information - The company completed three acquisitions mid-year, contributing to reported revenue growth of 18% for the full year [6] - The company achieved a full-year return on equity of 27% [8] Q&A Session Summary Question: Can you help us understand the durable aspects of Q4 results? - Management indicated that the run rate for EBITDA is approximately $110 million, with variability in Q4 not projected to continue [32] Question: Did the vaccine program contribute more this year than last year? - Management confirmed that the vaccine program continued to be significant in Q4, with improved profitability [34] Question: What progress has been made in balancing profit contributions between generics and branded drugs? - Management noted progress in aligning gross margin dollars with the high volume of generic prescriptions [36] Question: Is the gap between potential margin and realized margin still the same? - Management indicated that the gap has increased to approximately 90 basis points [37] Question: Can you discuss opportunities arising from competitors facing challenges? - Management acknowledged potential opportunities from competitors in distress, particularly in the context of ongoing bankruptcy processes [48] Question: Are you seeing efficiencies in labor costs? - Management stated that efficiencies are primarily due to scaling the existing platform rather than improvements in labor inflation [49] Question: How is the integration of recently acquired facilities progressing? - Management reported faster ramp-up and integration of recently acquired facilities, particularly in the Pacific Northwest [56] Question: What is the outlook for M&A opportunities given the current market conditions? - Management expressed a robust pipeline for M&A in 2026, while remaining disciplined in their approach [60]

Financial Data and Key Metrics Changes - In Q4 2025, net sales decreased by 2.4% to $1.52 billion, with comparable sales down 1.6% [9][10] - For the full year 2025, Adjusted EBITDA increased by 21.3% to $408 million, with a margin of 6.8% [8][9] - Operating cash flow rose by 77% year-over-year, contributing to a reduction in the leverage ratio from 4.2x to 3x [4][9] - Free cash flow improved by 276% to $187 million [9][12] Business Line Data and Key Metrics Changes - The company focused on moving away from unprofitable sales, resulting in a decline in total sales but improved profitability [10][12] - Gross margin rate expanded by 66 basis points to 38.7% for the full year 2025 [8] - Operating profit increased by $113 million, with operating margin expanding by 190 basis points [8] Market Data and Key Metrics Changes - The company ended 2025 with 1,382 stores in the U.S., following 25 net store closures in 2024 and 16 in 2025 [10] - The company expects net store closures between 15 and 20 in 2026, with closures weighted towards the latter half of the year [15] Company Strategy and Development Direction - The company is entering a new phase called "Reach for the Sky," focusing on sustainable top-line growth through four pillars: compelling product offerings, services at scale, trusted store experiences, and an integrated omni-channel model [18][19] - The strategy includes expanding the fresh food category, launching new national brands, and increasing the frequency of product drops [20][21][23] - The company aims to leverage its wholly owned services, including vet hospitals and grooming, as a key growth engine [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in starting 2026 from a position of strength despite a challenging macro environment [14] - The guidance for Q1 2026 anticipates net sales to be down 1% to flat, with Adjusted EBITDA expected between $92 million and $94 million [15][16] - Management emphasized that growth initiatives are designed to be self-help in nature, not reliant on favorable macro conditions [34] Other Important Information - The company has made significant progress in improving its economic model, focusing on profitability and cash generation [8][12] - The company plans to enhance its loyalty program and digital capabilities in 2026 [31][32] Q&A Session Questions and Answers Question: What will lead Petco's growth from here? - Management indicated that growth will come from all four pillars simultaneously, with product taking the longest to implement [37][39] Question: What are the drivers of the increase in gross margins? - Management highlighted the focus on pricing, promotions, and product mix as key levers for maintaining healthy margins [44][45] Question: How is the brand assortment evolving? - Management stated that the brand assortment is widening to cater to both premium and mainstream customers [52][54] Question: What percentage of customers engage in services? - Management noted that there is significant room for growth in services, particularly in vet hospitals and grooming [61][63] Question: How will the company capture customers who do not buy dog food? - Management emphasized the importance of cross-selling and leveraging customer data to increase sales among existing customers [66][67]

Financial Data and Key Metrics Changes - For the third fiscal quarter, the company reported revenue of $16.9 million, which is down from $18.9 million for the same period in the prior fiscal year and essentially the same as the second fiscal quarter of this fiscal year [13][19] - The revenue from commercial and U.S. government satellite programs was approximately $4.2 million, accounting for 25% of total revenue, compared to $11.2 million or 59% in the same period of the prior fiscal year [14] - Revenues from non-space U.S. government and Department of Defense customers were $12.5 million, representing 74% of consolidated revenue, up from 39% in the prior fiscal year [15] - Consolidated net income for the three months ended January 31, 2026, was approximately $1.6 million or $0.16 per share, compared to approximately $15.4 million or $1.60 per share for the same period of the previous fiscal year [20] Business Line Data and Key Metrics Changes - Revenue from satellite payload contracts was recognized primarily under the percentage of completion method and reported only in the FEI New York segment [15] - The company experienced a decrease in gross margin and gross margin rate due to a change in the mix of high-margin production satellite programs in the prior year versus lower-margin programs in the current period [16] - Selling, General, and Administrative (SG&A) expenses increased to approximately 21% of consolidated revenue, up from 18% in the prior year [17] Market Data and Key Metrics Changes - The company’s fully funded backlog at the end of January 2026 was approximately $83 million, a new all-time high, compared to approximately $70 million for the previous fiscal year [21] - The company anticipates that the new contracts announced will start to enter backlog in the current fiscal fourth quarter, contributing to the growth towards the $100 million backlog target [7][69] Company Strategy and Development Direction - The company is focusing on growth in large and growing end markets, including quantum sensing and proliferated satellites, alongside ongoing strength in space and defense businesses [3][4] - The management emphasized the importance of maintaining a balance between traditional and new business lines, expecting both to grow simultaneously [5] - The company is investing in R&D to keep its products at the state of the art, with plans to continue this investment in the future [18] Management's Comments on Operating Environment and Future Outlook - The management acknowledged the current geopolitical climate, including the ongoing war, which has increased reliance on traditional defense technologies [9][11] - There is an expectation for strong opportunities in both traditional defense and next-generation modalities, particularly in alternative positioning, navigation, and timing systems [11][12] - The management expressed optimism about the future growth of the TURbO program, indicating significant revenue potential [34][35] Other Important Information - The company is debt-free and believes its liquidity is adequate to meet operating and investing needs for the next 12 months [23] - The company has already collected over $11 million of cash since February 1, 2026, which is expected to continue building through the quarter [22] Q&A Session Summary Question: Insights on proliferated constellation deals - The management noted success in winning contracts where they can provide a technical edge, but emphasized challenges in low-cost environments [26][27] Question: Details on the $45 million contracts - The management indicated both contracts are significant but did not disclose specific proportions [28][29] Question: Cost structure and operating expenses - The management explained that investments in Colorado are a significant part of current operating expenses, which should normalize over time [31][32] Question: Updates on the TURbO program - The management expressed increased optimism about TURbO, expecting significant revenue growth in the near future [34][35] Question: Clarification on proliferated satellites - The management described proliferated satellites as systems with many more satellites, typically in low Earth orbit, designed to be less costly and more rapidly produced [40][42] Question: Addressing GPS jamming and alternative navigation - The management discussed ongoing projects in magnetic navigation and other non-satellite alternatives to GPS, indicating government interest and funding for these technologies [88][90]

Financial Data and Key Metrics Changes - For the full year 2025, net operating income increased by more than 22% and adjusted EBITDA per share improved by 28% [8][18] - The company realized a 5.9% increase in revenue per occupied room (RevPOR) for Q4 compared to the same quarter in the prior year, with an annual growth of 8.8% [18][19] - Total portfolio NOI at share grew by 22% or $15 million on an annualized basis [21] Business Line Data and Key Metrics Changes - The same-store portfolio saw an additional 20 basis points of sequential occupancy gains in Q4, following a 90 basis point increase in Q3 [18] - The acquisition portfolio experienced a 680 basis point occupancy jump from 2024, with community NOI margin expanding by 550 basis points to 24.7% [19][21] - The 19 communities acquired in 2024 showed a sequential occupancy improvement of 290 basis points from Q3 to Q4, with total occupancy improving by 820 basis points year-over-year [9] Market Data and Key Metrics Changes - The company anticipates accelerated occupancy gains as the 19 communities from the 2024 acquisition cohort move into the same-store portfolio in 2026 [19] - The average annual rent renewal rate on in-place leases for the recent March 1 renewal was 7.9%, applicable to 96% of total same-store residents, up from 6.8% the previous year [25] Company Strategy and Development Direction - The company completed the acquisition of CNL Healthcare Properties for a total consideration of $1.8 billion, enhancing competitive positioning and growth profile [5][6] - Plans are in place to prune approximately 10% of the portfolio based on community count, focusing on recycling capital into higher growth, newer vintage assets [22][39] - The company aims to maintain a focus on delivering excellent clinical care and services while developing a labor model that rewards strong employees [10][16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the merger's potential to drive improved performance trends and significant upside [10] - The company is targeting growth in revenue per occupied room at or above the same-store growth achieved in 2025 for the full year 2026 [8] - Management highlighted the importance of retaining and developing talent, with a focus on reducing employee turnover [16] Other Important Information - The company has committed to a new upsized $405 million revolver to increase available capital for investment opportunities [14] - The acquisition is expected to provide significant capital for reinvestment in both internal ROI projects and new acquisitions [13] Q&A Session Summary Question: Can you discuss the adjusted EBITDA and interest costs assumptions post-merger? - Management indicated that details will be provided in Q1, aiming for comparability with large-scale REIT reporters [37] Question: What is the timeline for pruning the 10% of the portfolio? - Management expects to make progress within a six to twelve-month timeline, with proceeds primarily used for deleveraging and reinvestment in higher quality assets [39] Question: Is the 16%-17% same-store NOI growth a good run rate number? - Management views this as a starting point for the new asset bucket, with further insights to be provided as normalized FFO metrics are released [40][41] Question: Is the 7.9% rate increase for the legacy pool or the current pool? - The rate increase is for the legacy pool that was implemented recently [46] Question: Will net lease assets be part of the dispositions this year? - Management stated there are no immediate plans to sell net lease assets but will evaluate market conditions for potential opportunities [49]

Financial Data and Key Metrics Changes - In Q4 2025, net sales decreased by 2.4% to $1.52 billion, with comparable sales down 1.6% [9][10] - For the full year 2025, Adjusted EBITDA increased by 21.3% to $408 million, with a margin of 6.8% [8][9] - Operating cash flow rose by 77% year-over-year, contributing to a reduction in the leverage ratio from 4.2x to 3x [4][9] - Free cash flow improved by 276% to $187 million [9][12] Business Line Data and Key Metrics Changes - The company focused on moving away from unprofitable sales, resulting in a decline in total sales but improved profitability [10][12] - Gross margin rate expanded by 66 basis points to 38.7% for the full year 2025 [8] - Operating profit increased by $113 million, with an operating margin expansion of 190 basis points [8] Market Data and Key Metrics Changes - The company ended 2025 with 1,382 stores in the U.S., following 25 net store closures in 2024 and 16 in 2025 [10] - The company expects net store closures between 15 and 20 in 2026, with closures weighted towards the latter half of the year [15][16] Company Strategy and Development Direction - The company is entering a new phase called "Reach for the Sky," focusing on sustainable top-line growth through four pillars: compelling product offerings, services at scale, trusted store experiences, and an integrated omni-channel model [18][19] - The strategy includes expanding the fresh food category, launching new national brands, and increasing the frequency of product drops [20][21][24] - The company aims to leverage its wholly owned vet services as a key growth engine, with plans to optimize existing locations and expand in 2027 [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in starting 2026 from a position of strength despite a challenging macro environment [14] - The guidance for Q1 2026 anticipates net sales to be down 1% to flat, with Adjusted EBITDA expected between $92 million and $94 million [15][16] - Management emphasized that growth initiatives are designed to be self-help in nature, not reliant on favorable macro conditions [34] Other Important Information - The company has made significant progress in improving its economic model, focusing on profitability and cash generation [8][12] - The management team has undergone changes, with new leadership contributing to a transformative year [5][6] Q&A Session Summary Question: What will lead Petco's growth from here? - Management indicated that growth will come from all four pillars simultaneously, with product development taking the longest to implement [37][39] Question: What are the drivers of the increase in gross margins? - Management highlighted the focus on pricing, promotions, and product mix as key levers for maintaining healthy gross margins [44][45] Question: How is the brand assortment evolving? - Management stated that the brand strategy is widening to cater to both premium and mainstream customers, ensuring a diverse product offering [52][54] Question: What percentage of customers engage in services? - Management noted that there is significant room for growth in services, particularly in veterinary services, which are currently available in about 20% of stores [61][63] Question: How will the company capture customers who do not currently buy dog food? - Management emphasized the importance of cross-selling and leveraging customer data to increase sales among existing customers [66][67]

Financial Data and Key Metrics Changes - Total revenues for Q4 2025 were $38.9 million, up from $21.5 million in Q4 2024, primarily due to a technology transfer agreement with Merck [21] - For the full year 2025, revenue was $70.4 million compared to $59.3 million in 2024 [21] - Product gross margin for Q4 2025 was 64%, consistent with the full year 2025 gross margin, which also stood at 64%, up from 56% in the prior year [22] - Net income for Q4 2025 was $9.6 million, compared to a net loss of $10.4 million in Q4 2024; net loss for the full year 2025 was $44 million, improved from a loss of $65.3 million in 2024 [24][25] Business Line Data and Key Metrics Changes - The small molecule biocatalysis business returned to a healthy profit margin, with stabilization in revenue, supported by a robust pipeline of drugs in late-stage clinical studies [10] - The ECO Synthesis platform achieved significant milestones, including synthesizing 10 grams of commercially relevant siRNA and scaling production to 100 grams, with plans to reach half a kilo by the end of 2026 [6][7] Market Data and Key Metrics Changes - The total addressable annual market for production technologies in five years is estimated to be $2 billion, with a growing demand for siRNA medicines at a rate of 5%-10% per year [5] - The industry is projected to require 10-30 metric tons of oligonucleotide material by 2030, indicating a significant addressable market for the company [57] Company Strategy and Development Direction - The company is focused on establishing itself as a key technology provider in the RNA medicine market through its ECO Synthesis platform, which aims to address challenges in siRNA production [4][5] - Plans include scaling up production capabilities, achieving GMP certification, and expanding partnerships with CDMOs to enhance manufacturing processes [8][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth potential of the ECO Synthesis platform and the overall siRNA market, highlighting the importance of innovation and customer collaboration [12][28] - The company aims to demonstrate proof of success through new contracts and licensing deals in 2026, while maintaining a focus on financial performance and expense management [27][29] Other Important Information - The company ended 2025 with $78.2 million in cash equivalents, expected to fund operations and capital expenditures through the end of 2027 [25] - A restructuring charge of $3.4 million was recorded in Q4 2025 as part of efforts to reduce operating costs and improve gross margins [24] Q&A Session Summary Question: Potential value of stereoisomer control - Management is actively exploring the biological activity of stereo configurations and plans to present data at the TIDES USA meeting, with several customers interested in collaboration [31][32] Question: Understanding the recent deal process - The recent deal involved a small organization with a cardiovascular asset, highlighting the long-term discussions and mutual excitement about the ECO Synthesis platform's capabilities [35][39] Question: Details on the 50-gram contract - The initial agreement is for preclinical work, with expectations that successful data will lead to IND submissions and larger contracts for clinical trials [41][43] Question: Revenue guidance visibility - Management indicated a significant portion of the $72 million-$76 million revenue guidance is based on historical buying practices, though some estimates remain speculative at the beginning of the year [50][51] Question: Growth expectations for biocatalysis business - The small molecule biocatalysis business is expected to stabilize and continue to fuel growth, while higher growth rates are anticipated from the ECO side of the business [62][65]

Financial Data and Key Metrics Changes - The company finished fiscal 2025 with total net sales of $155.1 million, an increase of 5.3% despite having 17 fewer stores than the previous year [11] - Comparable net sales for the fourth quarter increased by 10.1%, with physical stores and e-commerce contributing increases of 10.3% and 9.8% respectively [11] - Gross margin improved to 33.2% of net sales, an increase of 720 basis points compared to 26% last year [12] - Net income improved to $2.9 million or $0.10 per diluted share, compared to a net loss of $13.7 million or $0.45 per share last year [16] Business Line Data and Key Metrics Changes - Total net sales from physical stores increased by 3.6% despite a 7.1% reduction in store count, representing 72.3% of total net sales [12] - E-commerce net sales represented 27.7% of total net sales, up from 26.5% last year [12] - Product margins improved by 470 basis points due to higher initial markups and lower markdowns associated with reduced inventory [13] Market Data and Key Metrics Changes - The company experienced six consecutive months of positive comparable sales momentum, with 18 consecutive positive comp weeks [4] - February 2026 saw a comparable net sales increase of 20.1% compared to the same period in 2025 [17] Company Strategy and Development Direction - The company plans to open four to six new stores in fiscal 2026, shifting from a store closure strategy to a disciplined approach to growth [7] - Infrastructure investments and a price optimization tool have contributed to improved product margins and operational efficiencies [8] - The company is optimistic about its prospects for fiscal 2026, believing that the turnaround is real and fundamentals are fixed [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to sustain growth, although they acknowledged that macroeconomic conditions could impact discretionary retail spending [28] - The company expects further improvement in both top line and bottom line performance in each quarter of fiscal 2026 [10] - Management indicated that an annualized comparable net sales increase of approximately 8%-9% would be necessary to begin generating profitability for fiscal 2026 [19] Other Important Information - The company ended fiscal 2025 with total liquidity of $87.8 million, including cash of $46.3 million and no debt [16] - Total capital expenditures for fiscal 2025 were $4.7 million, down from $8.2 million in fiscal 2024 [16] Q&A Session Summary Question: Composition of strong comp for the fourth quarter - Management noted significant acceleration in comp sales from month to month, with strong performance across all departments and improved traffic [23] Question: What is driving higher traffic? - Management indicated strength across all categories, improved inventory levels, and effective marketing strategies as key drivers of higher traffic [25][26] Question: Path forward on store expansion - Management expressed confidence in unit economics and the ability to execute, while remaining cautious about the consumer spending environment [28] Question: CapEx for store expansion - Management expects CapEx to be in the range of $8 million-$9 million, with a focus on improving sales per square foot [29][43] Question: Assumptions for profitability outlook - Management clarified that an 8%-9% comp increase does not correlate to a proportionate increase in SG&A, and they expect to continue improving product margins [48]